Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-24
2011-05-24
Moore, Susanna (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S265100, C514S263220, C514S252160, C544S262000, C544S280000, C544S277000
Reexamination Certificate
active
07947695
ABSTRACT:
This invention comprises the novel compounds of formula (I)wherein R1, R2, R3, R4, R5, R6, Q1, Q2, X1, X2, Y and Z have defined meanings, having cell cycle kinase inhibiting enzymatic activity, their preparation, compositions containing them and their use as a medicine.
REFERENCES:
patent: 2004/0248905 (2004-12-01), Markwalder et al.
patent: 153976 (1985-09-01), None
patent: 1147108 (2001-10-01), None
patent: WO 98/16184 (1998-04-01), None
patent: WO 01/49688 (2001-07-01), None
patent: WO 03/063764 (2003-08-01), None
patent: WO 03/099820 (2003-12-01), None
patent: WO 2004/065378 (2004-08-01), None
patent: WO 2004/094426 (2004-11-01), None
patent: WO 2006/074985 (2006-07-01), None
Mahadevan et. al. (Expert Opinion, 2007, pp. 1011-1026).
Fischer et. al. (Expert Opin. Investig. Drugs, 2005, pp. 457-477).
Strecker et. al. (Expert Opin. Emerging Drugs, 2008, pp. 573-591).
Fischer, P.M., et al., “CDK inhibitors in clinical development for the treatment of cancer”, Expert Opin. Investig. Drugs, vol. 12, No. 6 (2003), pp. 955-970.
McLaughlin, F., et al., “The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age”, Drug Discovery Today, vol. 8, No. 17 (2003), pp. 793-802.
International Search Report PCT/EP2006/050097, mailed Apr. 3, 2006.
Freyne Eddy Jean Edgard
Lacrampe Jean Fernand Armand
Lardeau Delphine Yvonne Raymonde
Lavrijssen Tom
Ligny Yannick Aimé Eddy
Janssen Pharmaceutica NV
Moore Susanna
LandOfFree
5-membered annelated heterocyclic pyrimidines as kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-membered annelated heterocyclic pyrimidines as kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-membered annelated heterocyclic pyrimidines as kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2673664